ELIXIR-LU, the Luxembourgish node of ELIXIR, the European infrastructure for life science information, focuses on long-term sustainability of tools and data for Translational Medicine.

Translational Medicine data integrate clinical information with molecular and cellular data for a better understanding of diseases.

ELIXIR-LU aims to facilitate long-term access to those research data and to tools for scientists in both academia and industry. This will allow the reuse of previously generated data to address new research questions and dramatically save time and cost.

Elixir Luxembourg

Projects

ELIXIR-LU is involved in several large EU funded projects.

To know more...

 


Support and user training

Workshops and courses on data management, curation, analytics and visualisation. Continuous education of software developers, data managers and researchers.

To know more...

Services

Repository for high quality Translational Medicine data

Integration of well-curated clinical and molecular data from cohorts and large consortia. Implementation of standardised electronic data capture, data harmonisation and curation.

High-performance data access and computing services

Sustainable access management according to well-defined criteria, in order to meet the security and accountability requirements of ELIXIR, of the General European data protection regulation (GDPR), and of the research community. Platforms and tools to allow efficient data access and analysis.

Data catalog Tools Registry GDPR activities

Our news

ELIXIR-LU and LCSB contribute to the development of a European Health Data Space
HealthyCloud Advances in health and biomedical sciences require that health research is performed timely, efficiently and oriented to high-quality results. To meet this need and to maximise the impact of health resear... (read more)
ELIXIR-LU first EKES webinar with PetaGene
In November, ELIXIR-LU and PetaGene shared the first EKES (ELIXIR Knowledge Exchange Scheme) pilot outcome — a webinar on genomic data privacy. This workshop was the basis for future collaboration between Petagene and... (read more)

See more news...